A Phase 2, Double-Blind, Placebo-Controlled, Double-Dummy, Cross-Over Study to Investigate the Hypnotic Activity of Three Doses (10mg, 15mg, 20mg) of a New Zaleplon Prototype, SKP-1041, in Adults With Primary Insomnia.

Trial Profile

A Phase 2, Double-Blind, Placebo-Controlled, Double-Dummy, Cross-Over Study to Investigate the Hypnotic Activity of Three Doses (10mg, 15mg, 20mg) of a New Zaleplon Prototype, SKP-1041, in Adults With Primary Insomnia.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2013

At a glance

  • Drugs Zaleplon (Primary)
  • Indications Sleep maintenance insomnia
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Jun 2011 Status changed from active, no longer recruiting to completed.
    • 23 Mar 2011 Primary endpoint 'Wake-time-after-sleep-onset' has been met.
    • 05 Nov 2010 Results data are expected to be unblinded in the first half of 2011, according to a Somnus therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top